Intas and Accord BioPharma Acquire Coherus BioSciences’ UDENYCA

Intas Pharmaceuticals in collaboration with its global Accord brand subsidiaries, has acquired UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, Inc., becoming a leading supplier of pegfilgrastim.

UDENYCA, a biosimilar to Amgen’s Neulasta (pegfilgrastim), significantly expands Intas and Accord’s FDA-approved biosimilar portfolio and strategic growth plans in the global biosimilar market. Accord was the first to commercialize a pegfilgrastim biosimilar in Europe and the only company to launch an autoinjector. 

With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA, which is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. UDENYCA offers three patient-friendly administration options—autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS). 

The acquisition also brings talent from Coherus BioSciences employees across multiple functions, including Sales, Marketing, Finance, Supply Chain, and Quality and Manufacturing, who have joined Accord BioPharma.